UK calls for access to new AMD therapies

Article

Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
Related Content
A lightbulb hovering in an open box, in a room full of closed boxes. Image concept for "thinking outside the box," and revisiting or amending perspectives to treatment of retinal disease. Image credit: ©masterzphotofo – stock.adobe.com

Broader perspective for the treatment approach on retinal neovascular diseases

Fanka Gilevska, MD, PhD
October 11th 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

October 11th 2025
Podcast
An elderly woman with glasses sits on a grassy hillside, near a tranquil blue lake. Concept image for geographic atrophy and vision-related quality of life measures. ©CameraCraft – stock.adobe.com

Intravitreal complement inhibitor treatment for GA viewed favorably by patients

Lynda Charters
October 11th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

October 11th 2025
Podcast
Stela Vujosevic, Md, PhD, FEBO, speaks about the need for a new staging system in diabetic eye disease during the 2025 European Society of Retina Specialists (EURETINA) meeting in Paris, France.

EURETINA 2025: Diabetic eye disease needs a new staging system

Stela Vujosevic, Md, PhD, FEBO;Hattie Hayes;Sydney M Crago
October 11th 2025
Article
A hand writes a check mark in a box. It is superimposed over an image of samples in a laboratory. Image credit: ©everythingpossible – stock.adobe.com

European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9)

Martin David Harp
October 11th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.